The mutant Eisai hyperbilirubinemic rat is resistant to bile acid-induced cholestasis and cytotoxicity.
We investigated bile flow and biliary excretion of bile acids in the Eisai hyperbilirubinemic rat, a Sprague-Dawley mutant rat with conjugated hyperbilirubinemia, using both in vivo and in vitro models. In vivo bile flow was lower in Eisai hyperbilirubinemic rats than in the control rats before and after taurocholate was infused. After taurocholate was infused, bile acid output was similar in the Eisai hyperbilirubinemic rats and control rats. In the isolated perfused rat liver, biliary excretion of bile acids was higher in the Eisai hyperbilirubinemic rats than in the control rats after a high-dose infusion of taurocholate (0.33 mumol/min/gm liver). Infusion of taurochenodeoxycholate (0.22 mumol/min/gm liver) did not produce cholestasis and did not reduce the biliary excretion of bile acids in the Eisai hyperbilirubinemic rats. Taurochenodeoxycholate significantly increased the phospholipid/bile acid molar ratio and slightly reduced bile acid-induced alkaline phosphatase output into bile. The release of lactate dehydrogenase from the perfused liver 30 min after the start of the taurochenodeoxycholate infusion was 10 times lower in the Eisai hyperbilirubinemic rats than in the control rats (2.0 +/- 0.8 vs. 28.7 +/- 6.8 mU/min/gm liver). When the isolated perfused rat liver was infused with a 1-min pulse of horseradish peroxidase (25 mg), we observed an early and late peak of biliary excretion of horseradish peroxidase. The Eisai hyperbilirubinemic rats showed a significant increase in the late peak.(ABSTRACT TRUNCATED AT 250 WORDS)
Hoshino
M
M
First Department of Internal Medicine, Medical School, Nagoya City University, Japan.
Hayakawa
T
T
Hirano
A
A
Kamiya
Y
Y
Ohiwa
T
T
Tanaka
A
A
Kumai
T
T
Inagaki
T
T
Miyaji
M
M
Takeuchi
T
T
D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D001646:Bile / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D001647:Bile Acids and Salts / Q000009:adverse effects* / Q000378:metabolism; D002779:Cholestasis / Q000139:chemically induced*; D006735:Horseradish Peroxidase; D006932:Hyperbilirubinemia / Q000378:metabolism*; D066298:In Vitro Techniques; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008297:Male; D010743:Phospholipids / Q000378:metabolism; D051381:Rats; D011922:Rats, Mutant Strains; D017207:Rats, Sprague-Dawley; D013655:Taurochenodeoxycholic Acid / Q000009:adverse effects / Q000378:metabolism; D013656:Taurocholic Acid / Q000009:adverse effects / Q000378:metabolism
D001647:Bile Acids and Salts; D010743:Phospholipids; D013655:Taurochenodeoxycholic Acid; D013656:Taurocholic Acid; D007770:L-Lactate Dehydrogenase; D006735:Horseradish Peroxidase; D000469:Alkaline Phosphatase